Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)

Market Cap	2.75B
Revenue (ttm)	542.45M
Net Income (ttm)	41.90M
Shares Out	120.00M
EPS (ttm)	0.35
PE Ratio	65.60
Forward PE	n/a
Dividend	0.05 (0.22%)
Ex-Dividend Date	n/a

Volume	18,359,512
Average Volume	4,119,950
Open	22.01
Previous Close	23.19
Day's Range	22.01 - 27.48
52-Week Range	14.61 - 27.93
Beta	0.10
RSI	74.31
Earnings Date	Apr 21, 2025

About SHE:300584

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefotiam hydrochloride, and adenosine monophosphate for injection; voglibose tablets, ansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; and raw materials, intermediates, and other products. Its products a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 553
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300584

Financial Performance

In 2024, SHE:300584's revenue was 504.36 million, a decrease of -2.60% compared to the previous year's 517.83 million. Earnings were 40.22 million, an increase of 10.75%.